---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036753"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-08-10T12:40:31+00:00"
generated_at: "2026-08-10T12:45:24.988503+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech reports Q2 2026 net loss of $3.8M; completes Phase 2 pancreatic cancer enrollment

## Summary
- Q2 2026 net loss of $3.8M ($0.43/share) vs $2.8M ($3.68/share) in Q2 2025; cash $9.9M vs $3.0M at year-end 2025.
- Completed enrollment and Ampligen dosing in Phase 2 DURIPANC trial (metastatic pancreatic cancer) with AstraZeneca's Imfinzi.
- Engaged Thermo Fisher's PPD for Phase 3 study design; anticipates DURIPANC clinical benefit data Q1 2027, OS data Q3 2027.
- Ampligen showed median OS 34.8 months vs 12.5 months historical controls in Dutch Named Patient Program.
- Regained full compliance with NYSE American listing standards; planning Ebola virus disease initiatives.

## SEC filing metadata
- accession: 0001493152-26-036753
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-08-10T12:40:31+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/0001493152-26-036753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036753
- JSON: https://secwatch.observer/filing/0001493152-26-036753.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.